Eisai Newsroom http://eisai.mediaroom.com/ Eisai Newsroom New Data Highlight Innovative Ways to Assess Patients with Early Alzheimer's Disease and Later Stage Alzheimer's Disease Dementia http://eisai.mediaroom.com/2017-10-30-New-Data-Highlight-Innovative-Ways-to-Assess-Patients-with-Early-Alzheimers-Disease-and-Later-Stage-Alzheimers-Disease-Dementia Mon, 30 Oct 2017 07:55:00 -0400 http://eisai.mediaroom.com/2017-10-30-New-Data-Highlight-Innovative-Ways-to-Assess-Patients-with-Early-Alzheimers-Disease-and-Later-Stage-Alzheimers-Disease-Dementia Eisai Inc. and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commercialization of Eisai's Oncology and Neurology Products throughout Latin America http://eisai.mediaroom.com/2017-10-03-Eisai-Inc-and-Grupo-Biotoscana-Sign-Exclusive-Licensing-Agreement-for-the-Commercialization-of-Eisais-Oncology-and-Neurology-Products-throughout-Latin-America Tue, 03 Oct 2017 08:00:00 -0400 http://eisai.mediaroom.com/2017-10-03-Eisai-Inc-and-Grupo-Biotoscana-Sign-Exclusive-Licensing-Agreement-for-the-Commercialization-of-Eisais-Oncology-and-Neurology-Products-throughout-Latin-America FDA Accepts Supplemental New Drug Application for Eisai's Lenvatinib for the Treatment of Liver Cancer http://eisai.mediaroom.com/2017-09-26-FDA-Accepts-Supplemental-New-Drug-Application-for-Eisais-Lenvatinib-for-the-Treatment-of-Liver-Cancer - Lenvatinib, if approved, would be the first new systemic treatment for first-line use in patients with liver cancer in more than a decade Tue, 26 Sep 2017 14:23:00 -0400 http://eisai.mediaroom.com/2017-09-26-FDA-Accepts-Supplemental-New-Drug-Application-for-Eisais-Lenvatinib-for-the-Treatment-of-Liver-Cancer Michael Amoroso appointed Senior Vice President, Americas Commercial, Oncology Business Group at Eisai Inc. http://eisai.mediaroom.com/2017-09-25-Michael-Amoroso-appointed-Senior-Vice-President-Americas-Commercial-Oncology-Business-Group-at-Eisai-Inc Mon, 25 Sep 2017 08:00:00 -0400 http://eisai.mediaroom.com/2017-09-25-Michael-Amoroso-appointed-Senior-Vice-President-Americas-Commercial-Oncology-Business-Group-at-Eisai-Inc Combination of Lenvatinib and Pembrolizumab Results in Notable Response Rates for Patients with Advanced Renal Cell Carcinoma Based on Interim Analysis of Ongoing Phase 1b/2 Trial http://eisai.mediaroom.com/2017-09-10-Combination-of-Lenvatinib-and-Pembrolizumab-Results-in-Notable-Response-Rates-for-Patients-with-Advanced-Renal-Cell-Carcinoma-Based-on-Interim-Analysis-of-Ongoing-Phase-1b-2-Trial - Updated results of advanced RCC cohort from Study 111 support continued investigation of first-line use of the combination in ongoing Phase 3 CLEAR study Sun, 10 Sep 2017 08:30:00 -0400 http://eisai.mediaroom.com/2017-09-10-Combination-of-Lenvatinib-and-Pembrolizumab-Results-in-Notable-Response-Rates-for-Patients-with-Advanced-Renal-Cell-Carcinoma-Based-on-Interim-Analysis-of-Ongoing-Phase-1b-2-Trial